Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MUC1-mRNA dendritic cells
- Development stage
- Unknown
- Lead developer
- Mie University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
MUC1-mRNA dendritic cells (MUC1-DCs) is an autologous cell-based immunotherapy designed to treat cancers overexpressing the Mucin 1 (MUC1) glycoprotein, such as pancreatic adenocarcinoma. The therapy involves harvesting patient-derived monocytes, culturing them with GM-CSF and IL-4 to generate immature dendritic cells, and maturing them with TNF-α. These mature dendritic cells are then transfected with mRNA encoding the MUC1 antigen via electroporation. Once administered intradermally, these DCs present MUC1 epitopes to the patient's immune system, stimulating a targeted T-cell response against MUC1-positive tumor cells. Clinical studies have primarily evaluated this vaccine in combination with MUC1-specific cytotoxic T lymphocytes and gemcitabine for unresectable or recurrent pancreatic cancer.
- Other names
- MUC1-mRNA-transfected dendritic cellsMUC-1-mRNA-transfected dendritic cellsMUC 1-mRNA-transfected dendritic cellsMUC1-mRNA-loaded dendritic cellsMUC-1-mRNA-loaded dendritic cellsMUC 1-mRNA-loaded dendritic cells
02
Targets
CD28 (Cluster of Differentiation 28)IL-12R (Interleukin-12 receptor)MUC1 (Mucin-1 Antigen)TCR-MUC1 (T-cell receptor (TCR) recognizing MHC-MUC1 peptide complexes)
Beyond the preview
Go deeper on MUC1-mRNA dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MUC1-mRNA dendritic cells.